JW Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

JW Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.2M	Hold	388,392	–	–	3.82%	4
2026 Q1	$9.62M	Hold	388,392	–	–	3.95%	3
2025 Q4	$9.07M	Hold	388,392	–	–	2.95%	4
2025 Q3	$7.65M	Hold	388,392	–	–	3.67%	6
2025 Q2	$8.43M	Sell	388,392 -25,000	-6%	-$590K	4.15%	5
2025 Q1	$10M	Hold	413,392	–	–	5.68%	2
2024 Q4	$8.63M	Hold	413,392	–	–	4.1%	5
2024 Q3	$8.22M	Hold	413,392	–	–	3.71%	5
2024 Q2	$6.4M	Hold	413,392	–	–	2.64%	8
2024 Q1	$6.59M	Hold	413,392	–	–	2.41%	9
2023 Q4	$6.95M	Sell	413,392 -150,000	-27%	-$2.05M	3.97%	7
2023 Q3	$6.59M	Hold	563,392	–	–	2.85%	6
2023 Q2	$7.57M	Hold	563,392	–	–	2.76%	5
2023 Q1	$9.34M	Hold	563,392	–	–	3.58%	3
2022 Q4	$10.5M	Buy	+563,392	New	+$8.67M	4.31%	2

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JW Asset Management's CPRX Position: Q2 2026 in Review

JW Asset Management held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 388,392 shares worth $12.2M. The position accounts for 3.82% of the portfolio, ranked #4.

JW Asset Management first reported a position in CPRX in Q4 2022 and has held it in 15 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

JW Asset Management held 388,392 shares of Catalyst Pharmaceutical worth $12.2M as of Q2 2026.
JW Asset Management left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
Catalyst Pharmaceutical made up 3.82% of JW Asset Management's portfolio in Q2 2026, its #4 holding.
JW Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 15 quarters since.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on JW Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.